omniture
logo
Search
映恩生物DUALITYBIO
Media Room

Latest News

rss

DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors

SHANGHAI, Aug. 7, 2023 /PRNewswire/ -- Duality Biologics (Suzhou) Co. Ltd. ("DualityBio"), a clinic...

2023-08-07 18:00 1329

DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma with HER2 Overexpression

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Jan. 20, 2023 /PRNewswire/ -- Duality Biologics ("Dual...

2023-01-20 18:00 3344

Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo

* Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcend...

2023-01-05 09:00 1300

Duality announced the appointment of Dr. Pasi A. Jänne as Member of SAB

PRINCETON, N. J., SHANGHAI and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Duality Biotherapeutics...

2022-12-15 21:00 1668
Duality announced the appointment of Dr. Pasi A. Jänne as Member of SAB

Duality announced the appointment of Dr. Yver as Chairman of SAB

PRINCETON, N. J. and SHANGHAI, SUZHOU, China, Oct. 3, 2022 /PRNewswire/ -- Duality Biotherapeutics,...

2022-10-03 22:00 1619
Duality announced the appointment of Dr. Yver as Chairman of SAB

Duality Biologics Completed $90 Million Series B Financing

PRINCETON, N.J. and SHANGHAI and SUZHOU, China, May 19, 2021 /PRNewswire/ -- Duality Biologics (Dua...

2021-05-20 08:00 1612